Cargando…

Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level

PURPOSE: To explain the high inter-individual variability (IIV) and the frequency of exceeding the therapeutic reference range and the laboratory alert level of amisulpride, a population pharmacokinetic (PPK) model in Chinese patients with schizophrenia was built based on therapeutic drug monitoring...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Shanqing, Li, Lu, Wang, Zhanzhang, Xiao, Tao, Li, Xiaolin, Liu, Shujing, Zhang, Ming, Lu, Haoyang, Wen, Yuguan, Shang, Dewei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449641/
https://www.ncbi.nlm.nih.gov/pubmed/34548782
http://dx.doi.org/10.2147/DDDT.S327506
_version_ 1784569457580965888
author Huang, Shanqing
Li, Lu
Wang, Zhanzhang
Xiao, Tao
Li, Xiaolin
Liu, Shujing
Zhang, Ming
Lu, Haoyang
Wen, Yuguan
Shang, Dewei
author_facet Huang, Shanqing
Li, Lu
Wang, Zhanzhang
Xiao, Tao
Li, Xiaolin
Liu, Shujing
Zhang, Ming
Lu, Haoyang
Wen, Yuguan
Shang, Dewei
author_sort Huang, Shanqing
collection PubMed
description PURPOSE: To explain the high inter-individual variability (IIV) and the frequency of exceeding the therapeutic reference range and the laboratory alert level of amisulpride, a population pharmacokinetic (PPK) model in Chinese patients with schizophrenia was built based on therapeutic drug monitoring (TDM) data to guide individualized therapy. PATIENTS AND METHODS: Plasma concentration data (330 measurements from 121 patients) were analyzed using a nonlinear mixed-effects modeling (NONMEM) approach with first-order conditional estimation with interaction (FOCE I). The concentrations of amisulpride were detected by HPLC-MS/MS. Age, weight, sex, combination medication history and renal function status were evaluated as main covariates. The model was internally validated using goodness-of-fit, bootstrap and normalized prediction distribution error (NPDE). Recommended dosage regimens for patients with key covariates were estimated on the basis of Monte Carlo simulations and the established model. RESULTS: A one-compartment model with first-order absorption and elimination was found to adequately characterize amisulpride concentration in Chinese patients with schizophrenia. The population estimates of the apparent volume of distribution (V/F) and apparent clearance (CL/F) were 12.7 L and 1.12 L/h, respectively. Age significantly affected the clearance of amisulpride and the final model was as follows: CL/F=1.04×(AGE/32)(−0.624) (L/h). To avoid exceeding the laboratory alert level (640 ng/mL), the model-based simulation results showed that the recommended dose of amisulpride was no more than 600 mg/d for patients aged 60 years, 800 mg/d for those aged 40 years and 1200 mg/d for those aged 20 years, respectively. CONCLUSION: Dosage optimization of amisulpride can be carried out according to age to reduce the risk of adverse reactions. The model can be used as a suitable tool for designing individualized therapy for Chinese patients with schizophrenia.
format Online
Article
Text
id pubmed-8449641
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-84496412021-09-20 Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level Huang, Shanqing Li, Lu Wang, Zhanzhang Xiao, Tao Li, Xiaolin Liu, Shujing Zhang, Ming Lu, Haoyang Wen, Yuguan Shang, Dewei Drug Des Devel Ther Original Research PURPOSE: To explain the high inter-individual variability (IIV) and the frequency of exceeding the therapeutic reference range and the laboratory alert level of amisulpride, a population pharmacokinetic (PPK) model in Chinese patients with schizophrenia was built based on therapeutic drug monitoring (TDM) data to guide individualized therapy. PATIENTS AND METHODS: Plasma concentration data (330 measurements from 121 patients) were analyzed using a nonlinear mixed-effects modeling (NONMEM) approach with first-order conditional estimation with interaction (FOCE I). The concentrations of amisulpride were detected by HPLC-MS/MS. Age, weight, sex, combination medication history and renal function status were evaluated as main covariates. The model was internally validated using goodness-of-fit, bootstrap and normalized prediction distribution error (NPDE). Recommended dosage regimens for patients with key covariates were estimated on the basis of Monte Carlo simulations and the established model. RESULTS: A one-compartment model with first-order absorption and elimination was found to adequately characterize amisulpride concentration in Chinese patients with schizophrenia. The population estimates of the apparent volume of distribution (V/F) and apparent clearance (CL/F) were 12.7 L and 1.12 L/h, respectively. Age significantly affected the clearance of amisulpride and the final model was as follows: CL/F=1.04×(AGE/32)(−0.624) (L/h). To avoid exceeding the laboratory alert level (640 ng/mL), the model-based simulation results showed that the recommended dose of amisulpride was no more than 600 mg/d for patients aged 60 years, 800 mg/d for those aged 40 years and 1200 mg/d for those aged 20 years, respectively. CONCLUSION: Dosage optimization of amisulpride can be carried out according to age to reduce the risk of adverse reactions. The model can be used as a suitable tool for designing individualized therapy for Chinese patients with schizophrenia. Dove 2021-09-14 /pmc/articles/PMC8449641/ /pubmed/34548782 http://dx.doi.org/10.2147/DDDT.S327506 Text en © 2021 Huang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Huang, Shanqing
Li, Lu
Wang, Zhanzhang
Xiao, Tao
Li, Xiaolin
Liu, Shujing
Zhang, Ming
Lu, Haoyang
Wen, Yuguan
Shang, Dewei
Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level
title Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level
title_full Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level
title_fullStr Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level
title_full_unstemmed Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level
title_short Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level
title_sort modeling and simulation for individualized therapy of amisulpride in chinese patients with schizophrenia: focus on interindividual variability, therapeutic reference range and the laboratory alert level
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449641/
https://www.ncbi.nlm.nih.gov/pubmed/34548782
http://dx.doi.org/10.2147/DDDT.S327506
work_keys_str_mv AT huangshanqing modelingandsimulationforindividualizedtherapyofamisulprideinchinesepatientswithschizophreniafocusoninterindividualvariabilitytherapeuticreferencerangeandthelaboratoryalertlevel
AT lilu modelingandsimulationforindividualizedtherapyofamisulprideinchinesepatientswithschizophreniafocusoninterindividualvariabilitytherapeuticreferencerangeandthelaboratoryalertlevel
AT wangzhanzhang modelingandsimulationforindividualizedtherapyofamisulprideinchinesepatientswithschizophreniafocusoninterindividualvariabilitytherapeuticreferencerangeandthelaboratoryalertlevel
AT xiaotao modelingandsimulationforindividualizedtherapyofamisulprideinchinesepatientswithschizophreniafocusoninterindividualvariabilitytherapeuticreferencerangeandthelaboratoryalertlevel
AT lixiaolin modelingandsimulationforindividualizedtherapyofamisulprideinchinesepatientswithschizophreniafocusoninterindividualvariabilitytherapeuticreferencerangeandthelaboratoryalertlevel
AT liushujing modelingandsimulationforindividualizedtherapyofamisulprideinchinesepatientswithschizophreniafocusoninterindividualvariabilitytherapeuticreferencerangeandthelaboratoryalertlevel
AT zhangming modelingandsimulationforindividualizedtherapyofamisulprideinchinesepatientswithschizophreniafocusoninterindividualvariabilitytherapeuticreferencerangeandthelaboratoryalertlevel
AT luhaoyang modelingandsimulationforindividualizedtherapyofamisulprideinchinesepatientswithschizophreniafocusoninterindividualvariabilitytherapeuticreferencerangeandthelaboratoryalertlevel
AT wenyuguan modelingandsimulationforindividualizedtherapyofamisulprideinchinesepatientswithschizophreniafocusoninterindividualvariabilitytherapeuticreferencerangeandthelaboratoryalertlevel
AT shangdewei modelingandsimulationforindividualizedtherapyofamisulprideinchinesepatientswithschizophreniafocusoninterindividualvariabilitytherapeuticreferencerangeandthelaboratoryalertlevel